Zenas BioPharma · ISIN: US98937L1052

Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 -...

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

This news feed is a compilation of company-relevant news from the most popular and widest-reaching newswire services. The feed is updated several times. For market-related publications, we recommend the X-Billboard, the Daily News Digest or our Premium Information Service.
Most recent update: 12.08.2025 | 11:05
12 August 2025 11:05AM
Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 -...
Zenas BioPharma
© Globe Newswire
20 June 2025 08:15PM
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., June 20, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on June 16, 2025 (the “Grant Date”), the Compensation C...
Zenas BioPharma
© Globe Newswire
17 June 2025 04:00PM
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
NEW YORK, June 17, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are...
Zenas BioPharma
© PR Newswire
16 June 2025 06:47PM
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zenas BioPharma, Inc. (“Zenas” or “the Company”) (NASDAQ: ZBIO) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company’s Offering Documents is...
Zenas BioPharma
© BusinessWire
16 June 2025 04:41PM
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO) and reminds investors of the June 16, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi &am...
Zenas BioPharma
© BusinessWire
16 June 2025 03:07PM
ZBIO Investors Have Final Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, June 16, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zenas BioPharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws....
Zenas BioPharma
© PR Newswire
16 June 2025 11:45AM
June 16, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ZBIO
NEW YORK, June 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged...
Zenas BioPharma
© PR Newswire
16 June 2025 09:44AM
FINAL ALERT NOTICE - ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO
LOS ANGELES, June 16, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Zenas Biopharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws. Shareho...
Zenas BioPharma
© PR Newswire
15 June 2025 04:44PM
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Zenas To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Zenas pursuant and/or traceable to Zenas' registration statement for the initial public offering held on or...
Zenas BioPharma
© PR Newswire
13 June 2025 10:45PM
ZBIO Deadline: ZBIO Investors with Losses in Excess of $100K Have Opportunity to Lead Zenas BioPharma, Inc. Securities Lawsuit Filed by The Rosen Law Firm
NEW YORK, June 13, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement a...
Zenas BioPharma
© PR Newswire
13 June 2025 11:45AM
Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO
NEW YORK, June 13, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The law...
Zenas BioPharma
© PR Newswire
12 June 2025 03:00PM
MONDAY INVESTOR DEADLINE: Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - ZBIO
SAN DIEGO, June 12, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma's registration statement issued in connection with Zenas BioPharma's initial public offering (the "IPO") held on or aro...
Zenas BioPharma
© PR Newswire
12 June 2025 03:00PM
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
NEW YORK, June 12, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are...
Zenas BioPharma
© PR Newswire
12 June 2025 11:45AM
Investors who lost money on Zenas BioPharma, Inc.(ZBIO) should contact The Gross Law Firm about pending Class Action - ZBIO
NEW YORK, June 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged...
Zenas BioPharma
© PR Newswire
11 June 2025 04:24PM
ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO
LOS ANGELES, June 11, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Zenas Biopharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws. Shareho...
Zenas BioPharma
© PR Newswire
10 June 2025 03:42PM
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zenas To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Zenas pursuant and/or traceable to Zenas' registration statement for the initial public offering held on or about September 13...
Zenas BioPharma
© PR Newswire
10 June 2025 11:45AM
Zenas BioPharma, Inc. Class Action: Levi & Korsinsky Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 - ZBIO
NEW YORK, June 10, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The law...
Zenas BioPharma
© PR Newswire
09 June 2025 04:10PM
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES  , June 9, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zenas BioPharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws....
Zenas BioPharma
© PR Newswire
09 June 2025 11:45AM
Shareholders that lost money on Zenas BioPharma, Inc.(ZBIO) should contact The Gross Law Firm about pending Class Action - ZBIO
NEW YORK, June 9, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged...
Zenas BioPharma
© PR Newswire
09 June 2025 11:30AM
ZBIO INVESTOR NOTICE: Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit
SAN DIEGO, June 9, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma's registration statement issued in connection with Zenas BioPharma's initial public offering (the "IPO") held on or around September 13,...
Zenas BioPharma
© PR Newswire
07 June 2025 04:00PM
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
  NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail ar...
Zenas BioPharma
© PR Newswire
06 June 2025 08:57PM
ZBIO Deadline: ZBIO Investors with Losses in Excess of $100K Have Opportunity to Lead Zenas BioPharma, Inc. Securities Lawsuit Filed by The Rosen Law Firm
NEW YORK, June 6, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and...
Zenas BioPharma
© PR Newswire
06 June 2025 03:14PM
ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO
LOS ANGELES, June 6, 2025 /PRNewswire/ --  The DJS Law Group reminds investors of a class action lawsuit against Zenas Biopharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws. Shareho...
Zenas BioPharma
© PR Newswire
06 June 2025 03:13PM
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, June 6, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zenas BioPharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws....
Zenas BioPharma
© PR Newswire
06 June 2025 11:45AM
ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, June 6, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The laws...
Zenas BioPharma
© PR Newswire
05 June 2025 11:45AM
Shareholders that lost money on Zenas BioPharma, Inc.(ZBIO) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
NEW YORK, June 5, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged...
Zenas BioPharma
© PR Newswire
04 June 2025 03:40PM
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Zenas To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Zenas pursuant and/or traceable to Zenas' registration statement for the initial public offering held on or...
Zenas BioPharma
© PR Newswire
02 June 2025 03:10PM
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, June 2, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zenas BioPharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws....
Zenas BioPharma
© PR Newswire
02 June 2025 10:00AM
ZBIO INVESTOR ALERT: Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit
SAN DIEGO, June 2, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma's registration statement issued in connection with Zenas BioPharma's initial public offering ("IPO") held on or around S...
Zenas BioPharma
© PR Newswire
02 June 2025 10:00AM
ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO
LOS ANGELES, June 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Zenas Biopharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws. Sharehol...
Zenas BioPharma
© PR Newswire
01 June 2025 04:00PM
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
NEW YORK, June 1, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are...
Zenas BioPharma
© PR Newswire
31 May 2025 08:30PM
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Lawsuit Filed by The Rosen Law Firm
NEW YORK, May 31, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and...
Zenas BioPharma
© PR Newswire
31 May 2025 02:55PM
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zenas To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Zenas pursuant and/or traceable to Zenas' registration statement for the initial public offering held on or about September 13...
Zenas BioPharma
© PR Newswire
30 May 2025 11:45AM
Levi & Korsinsky Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 - ZBIO
NEW YORK, May 30, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The laws...
Zenas BioPharma
© PR Newswire
29 May 2025 11:45AM
Shareholders of Zenas BioPharma, Inc. Should Contact The Gross Law Firm Before June 16, 2025 to Discuss Your Rights - ZBIO
NEW YORK, May 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged...
Zenas BioPharma
© PR Newswire
29 May 2025 11:05AM
Zenas BioPharma to Present at the Jefferies Global Healthcare Conference
WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced management’s presentation at the Jefferies Global Healthcare...
Zenas BioPharma
© Globe Newswire
28 May 2025 05:25PM
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, May 28, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zenas BioPharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws....
Zenas BioPharma
© PR Newswire
28 May 2025 03:31PM
ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO
LOS ANGELES, May 28, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Zenas Biopharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws. Sharehol...
Zenas BioPharma
© PR Newswire
28 May 2025 02:52AM
ZBIO STOCKHOLDERS: Contact Robbins LLP for Information About How to Lead the Class Action Against Zenas BioPharma, Inc.
SAN DIEGO, May 27, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons who purchased or otherwise acquired Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma's September 202...
Zenas BioPharma
© PR Newswire
27 May 2025 04:20PM
ZBIO INVESTOR DEADLINE: Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
SAN DIEGO, May 27, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma's registration statement issued in connection with Zenas BioPharma's initial public offering ("IPO") held on or around September 13, 202...
Zenas BioPharma
© PR Newswire
27 May 2025 03:32PM
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, May 27, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zenas BioPharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws....
Zenas BioPharma
© PR Newswire
26 May 2025 04:00PM
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
NEW YORK, May 26, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are e...
Zenas BioPharma
© PR Newswire
26 May 2025 03:00PM
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Lawsuit Filed by The Rosen Law Firm
NEW YORK, May 26, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and...
Zenas BioPharma
© PR Newswire
23 May 2025 03:39PM
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, May 23, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zenas BioPharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws....
Zenas BioPharma
© PR Newswire
23 May 2025 11:45AM
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 16, 2025 in Zenas BioPharma, Inc. Lawsuit - ZBIO
NEW YORK, May 23, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The laws...
Zenas BioPharma
© PR Newswire
22 May 2025 11:45AM
The Gross Law Firm Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 - ZBIO
NEW YORK, May 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged...
Zenas BioPharma
© PR Newswire
22 May 2025 12:34AM
ZBIO Deadline: ZBIO Investors with Losses in Excess of $100K Have Opportunity to Lead Zenas BioPharma, Inc. Lawsuit Filed by The Rosen Law Firm
NEW YORK, May 21, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and...
Zenas BioPharma
© PR Newswire
20 May 2025 03:00PM
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
NEW YORK, May 20, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are...
Zenas BioPharma
© PR Newswire

The information service offers company-relevant news from leading newswire services in a compact form for a quick overview. When the detailed view is called up, further information can be accessed if required. The navigation elements in previewer mode allow you to quickly switch to the most frequently visited tool sections. From there, you can access further areas that can be used for your own research and analysis. Tip: The information platform now includes more than 50 mini-apps developed in-house.

AI First: Feel free to test the AI integration that will quickly put you on a par with financial journalists and research houses

Further information

The information presented in this section is secondary publications. The content corresponds to the source information. You can find information on the author of the news item in the detailed information of a publication. News relating to listed companies may have been created due to regulatory publication obligations, due to regular public relations work for PR or marketing reasons or by third parties against the background of investor information.

The combination of information and graphic elements contributes significantly to visual orientation and navigation through complex issues. This makes it easier to grasp, contextualize and process key content. Images, logos and other or comparable graphic and textual elements used on the information portal are used for visual navigation, are part of the original message or have illustrative purposes. All rights to these elements are held by the respective owners of the trademark or image rights. They are used without intent to infringe copyright or intellectual property rights. Image material provided via the distribution networks is treated as part of the original message and processed accordingly.

If you believe that copyright or intellectual property rights have been infringed by the presentation, please contact us immediately to clarify your concerns.